Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?Zacks Investment Research • 06/25/24
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA ApprovalInvestors Business Daily • 06/24/24
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating PolyneuropathyGlobeNewsWire • 06/21/24
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients' during its Upcoming R&D Day on July 16, 2024GlobeNewsWire • 06/17/24
argenx Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/09/24
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024GlobeNewsWire • 05/02/24
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune DiseaseGlobeNewsWire • 04/16/24
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's DiseaseGlobeNewsWire • 03/27/24
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune ThrombocytopeniaGlobeNewsWire • 03/26/24
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test ResultsInvestors Business Daily • 03/21/24
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual MeetingGlobeNewsWire • 03/07/24
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewsWire • 02/29/24
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024GlobeNewsWire • 02/22/24